Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SERA
Strong SellSinkerSera Prognostics, Inc. · Healthcare · United States · $82M · Avg Vol: $58K/d
14
StockRankGet insider-trade alerts
Q
20
V
31
M
42
P/E (TTM)
—
ROE
-45.0%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.3M | 0.3M | 77.0K | 81.0K | -32.9% | 70.0K | 0.2M | 1.9M | 387.5% |
| EPS | -1.43 | -1.16 | -0.99 | -0.67 | — | -0.66 | -0.66 | -0.54 | — |
| Shares | 31.0M | 31.7M | 34.2M | 38.9M | +25.6% | 38.5M | — | — | — |
| Debt | 2.8M | 1.9M | 0.8M | 2.3M | -6.2% | 3.0M | — | — | — |
| Equity | 98.9M | 70.2M | 47.8M | 75.4M | -8.7% | — | — | — | — |
| Op CF | -34.6M | -27.2M | -14.2M | -25.6M | — | -27.7M | — | — | — |
| Inv CF | 5.6M | 0.4M | 11.7M | -28.5M | — | — | — | — | — |
| Fin CF | 5.0K | 0.8M | 2.6M | 54.0M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-2.4%
SMA 50SMA 200
Close
$2.00
RSI (14)
50.8
52W High
$3.95
From 52W High
0.5%
SCORE BREAKDOWN
Quality
20
ROIC
-41.3%19.2
ROE
-45.0%20.0
GP/Assets
-0.1%8.9
Op. Margin
-33346.7%1.3
FCF/Assets
-27.1%15.8
Piotroski
25.9
Int. Cover
-50.0x5.9
D/E Ratio
0.05x70.8
Current Ratio
1.98x38.3
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-1.0x25.0
P/FCF
—N/A
P/B
1.3x77.3
P/S
1138.4x2.1
Div Yield
—N/A
Momentum
42
52W High %
51%23.8
RS 6M
-4%60.6
SMA 50/200
0.86x24.7
EPS Rev 4W
+7.2%86.5
EPS Rev 12W
—N/A
EPS Improve
+19%33.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$82M
P/E (Forward)
-3.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SERA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SERA | Sera Prognostics, Inc.(you) | $82M | 14 | Strong Sell |
| HYPR | Hyperfine, Inc. | $88M | 12 | Strong Sell |
| CVRX | CVRx, Inc. | $79M | 9 | Strong Sell |
| QTRX | Quanterix Corporation | $125M | 14 | Strong Sell |
| RPID | Rapid Micro Biosystems, Inc. | $79M | 6 | Strong Sell |
| ELUT | Elutia Inc. | $51M | 13 | Strong Sell |
| MBOT | Microbot Medical Inc. | $99M | 7 | Strong Sell |
| MDAI | Spectral AI, Inc. | $51M | 12 | Strong Sell |
| OM | Outset Medical, Inc. | $74M | 24 | Sell |
| COCH | Envoy Medical, Inc. | $53M | 10 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%